Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Projecting the Number of Patients with Colorectal Carcinoma by Phases of Care in the US: 2000-2020

Angela B. Mariotto, K. Robin Yabroff, Eric J. Feuer, Roberta De Angelis and Martin Brown
Cancer Causes & Control
Vol. 17, No. 10 (Dec., 2006), pp. 1215-1226
Published by: Springer
Stable URL: http://www.jstor.org/stable/29736577
Page Count: 12
  • Download ($43.95)
  • Cite this Item
Preview not available
Preview not available

Abstract

Objective This study provides projections of colorectal cancer prevalence by phases of care (initial, monitoring, and last year of life) to the year 2020 and describes the estimation method. Methods Cancer prevalence by phase of care was estimated from colorectal cancer incidence and survival from the Surveillance, Epidemiology, and End Results (SEER) Program data, population estimates and projections from the US Census Bureau, and all cause mortality data from the Human Mortality Life Tables. Assumptions of constant incidence and survival were used for projections from 2000 to 2020. Modeled and directly observed patient months by phase of care were compared for 1996-1998 to provide validation of estimates. Results Prevalence of colorectal cancer is estimated to increase from 1,002,786 (0.36%) patients to 1,522,348 (0.46%) patients between 2000 and 2020. The estimated number of person-months in the initial and last year of life phases of care will increase 43%, while the monitoring phase of care will increase 54%. Modeled person-months by phase of care were consistent with directly observed measures of person months by phase of care in 1996-1998. Conclusions Under assumptions of current cancer control strategies we project that colorectal cancer prevalence will increase more rapidly than the US population, largely due to the aging of the US population. This suggests that considerable resources will be needed in the future for initial, continuing and last year of life treatment of colorectal cancer patients unless notable breakthroughs in primary prevention occur in the future years.

Page Thumbnails

  • Thumbnail: Page 
[1215]
    [1215]
  • Thumbnail: Page 
1216
    1216
  • Thumbnail: Page 
1217
    1217
  • Thumbnail: Page 
1218
    1218
  • Thumbnail: Page 
1219
    1219
  • Thumbnail: Page 
1220
    1220
  • Thumbnail: Page 
1221
    1221
  • Thumbnail: Page 
1222
    1222
  • Thumbnail: Page 
1223
    1223
  • Thumbnail: Page 
1224
    1224
  • Thumbnail: Page 
1225
    1225
  • Thumbnail: Page 
1226
    1226